NRNP 6675
Las últimas cargas en NRNP 6675. ¿Buscando notas en NRNP 6675? Tenemos muchas notas, guias de estudio y notas de estudio disponsible para tu escuela.
-
1697
- 0
-
213
All courses for NRNP 6675
-
NRNP 6675 5
-
NRNP - 6675 1
-
NRNP 6675 1695
-
NRNP 6675 , 1
-
NRNP 6675 1
-
NRNP 6675, 1
-
NRNP 6675/ 3
-
NRNP-6675 2
Último contenido NRNP 6675
NRNP 6675 Final Exam (2 Versions, 200 Q & A, Latest-2022/2023) / NRNP 6675N Final Exam / NRNP6675 Final Exam / NRNP-6675N Final Exam: Walden University | 100% Verified Q & A|
- Examen
- • 113 páginas's •
-
NRNP 6675•NRNP 6675
Vista previa 4 fuera de 113 páginas
Preparando tu documento...
NRNP 6675 Final Exam (2 Versions, 200 Q & A, Latest-2022/2023) / NRNP 6675N Final Exam / NRNP6675 Final Exam / NRNP-6675N Final Exam: Walden University | 100% Verified Q & A|
NRNP 6675 FINAL EXAM (VERSION-2, 100 Q & A, 
LATEST-2023/2024) / NRNP6675 FINAL EXAM: 
WALDEN UNIVERSITY 
NRNP 6675 FINAL EXAM (VERSION-2, 100 Q & A, 
LATEST-2023/2024) / NRNP6675 FINAL EXAM: 
WALDEN UNIVERSITY
- Examen
- • 34 páginas's •
-
NRNP 6675•NRNP 6675
Vista previa 4 fuera de 34 páginas
Preparando tu documento...
NRNP 6675 FINAL EXAM (VERSION-2, 100 Q & A, 
LATEST-2023/2024) / NRNP6675 FINAL EXAM: 
WALDEN UNIVERSITY 
NRNP 6675 FINAL EXAM (VERSION-2, 100 Q & A, 
LATEST-2023/2024) / NRNP6675 FINAL EXAM: 
WALDEN UNIVERSITY
NRNP 6675 Week 6 Midterm Exam Latest Questions and Answers (2023/2024) (Verified Answers) 
 
1.	Which of the following are risk factors for neuroleptic malignant syndrome? Select all that apply Age 
Rapid dose escalation 
 
Parental route of administration 
 
Higher potency typical antipsychotics 
 
 
 
 
2.	Antipsychotic medications provide D2 blockade in the mesocortical pathway causing which of the following effects? 
 
Reduces negative symptoms 
 
Increases extra pyramidal symptoms (EPS) Cau...
- Examen
- • 29 páginas's •
-
NRNP 6675•NRNP 6675
Vista previa 3 fuera de 29 páginas
Preparando tu documento...
NRNP 6675 Week 6 Midterm Exam Latest Questions and Answers (2023/2024) (Verified Answers) 
 
1.	Which of the following are risk factors for neuroleptic malignant syndrome? Select all that apply Age 
Rapid dose escalation 
 
Parental route of administration 
 
Higher potency typical antipsychotics 
 
 
 
 
2.	Antipsychotic medications provide D2 blockade in the mesocortical pathway causing which of the following effects? 
 
Reduces negative symptoms 
 
Increases extra pyramidal symptoms (EPS) Cau...
NRNP 6675 Week 6 Midterm Exam Latest Questions and Answers (2023/2024) (Verified Answers) 
 
1.	Which of the following are risk factors for neuroleptic malignant syndrome? Select all that apply Age 
Rapid dose escalation 
 
Parental route of administration 
 
Higher potency typical antipsychotics 
 
 
 
 
2.	Antipsychotic medications provide D2 blockade in the mesocortical pathway causing which of the following effects? 
 
Reduces negative symptoms 
 
Increases extra pyramidal symptoms (EPS) Cau...
- Examen
- • 29 páginas's •
-
NRNP 6675•NRNP 6675
Vista previa 3 fuera de 29 páginas
Preparando tu documento...
NRNP 6675 Week 6 Midterm Exam Latest Questions and Answers (2023/2024) (Verified Answers) 
 
1.	Which of the following are risk factors for neuroleptic malignant syndrome? Select all that apply Age 
Rapid dose escalation 
 
Parental route of administration 
 
Higher potency typical antipsychotics 
 
 
 
 
2.	Antipsychotic medications provide D2 blockade in the mesocortical pathway causing which of the following effects? 
 
Reduces negative symptoms 
 
Increases extra pyramidal symptoms (EPS) Cau...
NRNP 6675 Week 6 Midterm Exam Latest Questions and Answers (2023/2024) (Verified Answers) 
 
1.	Which of the following are risk factors for neuroleptic malignant syndrome? Select all that apply Age 
Rapid dose escalation 
 
Parental route of administration 
 
Higher potency typical antipsychotics 
 
 
 
 
2.	Antipsychotic medications provide D2 blockade in the mesocortical pathway causing which of the following effects? 
 
Reduces negative symptoms 
 
Increases extra pyramidal symptoms (EPS) Cau...
- Examen
- • 29 páginas's •
-
NRNP 6675•NRNP 6675
Vista previa 3 fuera de 29 páginas
Preparando tu documento...
NRNP 6675 Week 6 Midterm Exam Latest Questions and Answers (2023/2024) (Verified Answers) 
 
1.	Which of the following are risk factors for neuroleptic malignant syndrome? Select all that apply Age 
Rapid dose escalation 
 
Parental route of administration 
 
Higher potency typical antipsychotics 
 
 
 
 
2.	Antipsychotic medications provide D2 blockade in the mesocortical pathway causing which of the following effects? 
 
Reduces negative symptoms 
 
Increases extra pyramidal symptoms (EPS) Cau...
NRNP 6675 FINAL EXAM (VERSION-2, 100 Q & A, 
LATEST-2023/2024) / NRNP6675 FINAL EXAM: 
WALDEN UNIVERSITY 
NRNP 6675 FINAL EXAM (VERSION-2, 100 Q & A, 
LATEST-2023/2024) / NRNP6675 FINAL EXAM: 
WALDEN UNIVERSITY
- Package deal
- Examen
- • 34 páginas's •
-
NRNP 6675•NRNP 6675
-
BUNDLE FOR NRNP 6675 Final Exam, Latest-2024/ WALDEN UNIVERSITY Exam• Por DrMedinaReiss
Vista previa 4 fuera de 34 páginas
Preparando tu documento...
NRNP 6675 FINAL EXAM (VERSION-2, 100 Q & A, 
LATEST-2023/2024) / NRNP6675 FINAL EXAM: 
WALDEN UNIVERSITY 
NRNP 6675 FINAL EXAM (VERSION-2, 100 Q & A, 
LATEST-2023/2024) / NRNP6675 FINAL EXAM: 
WALDEN UNIVERSITY
NRNP 6675 Week 6 Midterm Exam Latest Questions and Answers (2023/2024) (Verified Answers)(GRADED A+) 
1. Which of the following are risk factors for neuroleptic malignant syndrome? Select all that apply 
Age 
Rapid dose escalation 
Parental route of administration 
Higher potency typical antipsychotics 
 
2. Antipsychotic medications provide D2 blockade in the mesocortical pathway causing which of the 
following effects? 
Reduces negative symptoms 
Increases extra pyramidal symptoms (EPS) 
Caus...
- Examen
- • 29 páginas's •
-
NRNP 6675•NRNP 6675
Vista previa 3 fuera de 29 páginas
Preparando tu documento...
NRNP 6675 Week 6 Midterm Exam Latest Questions and Answers (2023/2024) (Verified Answers)(GRADED A+) 
1. Which of the following are risk factors for neuroleptic malignant syndrome? Select all that apply 
Age 
Rapid dose escalation 
Parental route of administration 
Higher potency typical antipsychotics 
 
2. Antipsychotic medications provide D2 blockade in the mesocortical pathway causing which of the 
following effects? 
Reduces negative symptoms 
Increases extra pyramidal symptoms (EPS) 
Caus...
NRNP 6675: Week 6: Midterm Exam 
1.	Mass Media Research began when?: Late 1920s and 1930s
- Examen
- • 36 páginas's •
-
NRNP 6675•NRNP 6675
Vista previa 4 fuera de 36 páginas
Preparando tu documento...
NRNP 6675: Week 6: Midterm Exam 
1.	Mass Media Research began when?: Late 1920s and 1930s
NRNP 6675 Mid term exam 2023 
1.	Discrepancy between anatomical sex and gender is known as?: B) Gender Discordance
- Examen
- • 113 páginas's •
-
NRNP 6675•NRNP 6675
Vista previa 4 fuera de 113 páginas
Preparando tu documento...
NRNP 6675 Mid term exam 2023 
1.	Discrepancy between anatomical sex and gender is known as?: B) Gender Discordance
1. Concerns when treating geriatric patients with psychotherapeutic drugs include 
all of the following 
EXCEPT: 
 A. Elderly persons may be more susceptible to adverse effects of psychotherapeutic 
drugs. 
 B. Elderly persons may metabolize psychotherapeutic drugs more slowly. 
C. Elderly persons may metabolize psychotherapeutic drugs more rapidly. 
 D. Elderly persons may excrete psychotherapeutic drugs more slowly. 
Question 2 
The treatment of others equitably and distribution of benefits/bu...
- Examen
- • 86 páginas's •
-
NRNP 6675•NRNP 6675
Vista previa 4 fuera de 86 páginas
Preparando tu documento...
1. Concerns when treating geriatric patients with psychotherapeutic drugs include 
all of the following 
EXCEPT: 
 A. Elderly persons may be more susceptible to adverse effects of psychotherapeutic 
drugs. 
 B. Elderly persons may metabolize psychotherapeutic drugs more slowly. 
C. Elderly persons may metabolize psychotherapeutic drugs more rapidly. 
 D. Elderly persons may excrete psychotherapeutic drugs more slowly. 
Question 2 
The treatment of others equitably and distribution of benefits/bu...